Home / Letter From The Editor / Dec. 23, 2017

Dec. 23, 2017

Dec 23, 2017
 

Happy holidays from the entire staff here at Diabetes in Control.

This week we add another SGLT-2 inhibitor to our armada of diabetes medications. This new drug, Ertugliflozin, (see news flash) is coming to the market as a stand alone and in combination with both a DPP-4 inhibitor and Metformin. We will wait to see final pricing, but there is a chance for some patients that the SGLT-2/DPP-4 combination could be a really good choice.

The problem with this is, even though you are getting two new class drugs in one pill, will the patient be able to afford it; or more importantly will it be on their formulary? This week we have a special feature that looks at the cost of nonadherence in lives and dollars, that has its roots in patients dropping off of medications that they simply can’t afford.
*****************************

We can make a difference!

*****************************

Dave Joffe

Editor-in-chief